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IMAGE study, 7 hospital deaths occurred in 434 placebo-
treated patients (1.6%). This is similar to the 1.8% hospital
mortality reported for non-aprotinin treated patients by
Weightman and Newman. However, aprotinin-treated
patients in the IMAGE study had a substantially lower hospi-
tal mortality than those patients treated with a comparable
dose (‡ 4,000,000 KIU) in Weightman and Newman’s letter:
1.4% compared with 11.5%.
Weightman and Newman report that of 754 patients receiv-
ing aprotinin, 93% received less than 4,000,000 KIU of apro-
tinin (see their Table I). Their reporting of the total dose
makes unclear the administration regimen (ie, pump only,
half dose, or full dose, as in the IMAGE study) and timing
(from the beginning of the operation, as recommended, or,
perhaps, after loss of hemostasis). Furthermore, and with the
exception of pump-only administration, aprotinin is typically
administered as a constant infusion per hour. In the simplest
scenario (no pump or loading dose), any differences in the
amount of aprotinin administered would result wholly from
the length of the operation. 
The variables that separated European from US patients in the
IMAGE study were primarily related to adverse angiographic
characteristics of the recipient vessels in addition to female sex,
older age, prior aspirin use, and abnormal left ventricular ejec-
tion fraction. The only predictor variables in the IMAGE study
for which there are data in Weightman and Newman’s patient
population (Anesth Analg 1999;88:286-91) are age, sex, and
aspirin use. Their patients were older than those in the IMAGE
study (63.8 years compared with 61.6 years at US sites and 62.0
years at Danish and Israeli sites), had a higher proportion of
women (20.5% compared with 9.4% at US sites and 14.3% at
Danish and Israeli sites), and a higher proportion of aspirin
users (58.8% compared with 42.8% at US sites and 26.1% at
Danish and Israeli sites). In the IMAGE study, aspirin use was
associated with a lower risk of graft occlusion, whereas the
other 2 variables, sex and age, were consistent with patients
having a higher risk for vein graft occlusion. Comparative data
on Weightman and Newman’s patient characteristics are too
limited to determine whether responses are more similar to
those observed in our European or US patient populations. It is
also unclear whether Weightman and Newman’s data are
prospective or retrospective.
These differences suggest that patients in Weightman and
Newman’s population—and particularly those receiving
aprotinin—had a more adverse patient profile than either US
or European patients in the IMAGE study or there were other
technical differences in the surgical procedures. Thus infer-
ences should not be made from a nonrandomized study, par-
ticularly one with apparent treatment biases.
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Abciximab (ReoPro) removal with a hemoconcen-
trator during cardiopulmonary bypass 
To the Editor:
The problem of performing emergency cardiac surgery on
patients who have been recently treated with abciximab
(ReoPro, Eli Lilly and Company, Indianapolis, Ind) as
addressed by Poullis and associates1 is indeed of considerable
interest to surgeons. The in vitro experiment they described,
however, may have limited applicability to the clinical situa-
tion of operating on a patient who has been recently treated
with abciximab. In their method, abciximab was added to a
solution of saline and then subjected to hemoconcentration
during circulation in an in vitro cardiopulmonary bypass cir-
cuit. However, platelets were not included in the test solution.
This protocol is quite different from the situation of a patient
who has been recently treated with abciximab and who does
have platelets.
Poullis and associates state that the purpose of hemofiltra-
tion is to remove free abciximab so that subsequently admin-
istered donor platelets will have the role of providing hemo-
stasis rather than “primarily absorbing free antibody.” This
hypothesis, however, is not consistent with the pharmacody-
namic profile of abciximab.
When abciximab is administered, the drug rapidly
binds to the platelet glycoprotein IIb/IIIa receptors and
results in severe inhibition of platelet aggregation and pro-
longation of the bleeding time.2,3 The binding of abciximab
to the platelets is noncompetitive and the dissociation rate
from platelets is slow. Excess non-bound abciximab is
rapidly cleared, and within 30 minutes of abciximab ad-
ministration less than 4% of the administered dose is pre-
sent within the serum as free antibody.4 Thus essentially no
abciximab is available for removal by hemofiltration.
Likewise, when donor platelets are transfused, no free
abciximab is present to be “absorbed.” When platelets are
transfused there is, however, redistribution of abciximab
from native (bound) platelet receptors to transfused (un-
bound) platelet receptors, resulting in an overall reduction
in the percentage of bound receptors. When this overall
percentage of blocked receptors falls below approximately
80%, the bleeding time and hemostasis return toward nor-
mal. This is the rationale for transfusing platelets to reverse
the effect of abciximab.3,4
Potential methods to reduce the bleeding diathesis in
patients requiring surgery while under the effect of abcix-
imab are welcome to surgeons who have to deal with this
problem. At present, however, platelet administration to
dilute the abciximab blockade of the platelet glycoprotein
IIb/IIIa receptors would appear to be the antidote of choice.
My colleagues and I5 recently reported experience with 12
patients who required emergency coronary artery bypass
grafting shortly after abciximab treatment. The routine
transfusion of 1 apheresis platelet unit (volume equal to 6
random donor platelets but acquired from a single donor)
after reversal of heparin effect by protamine, with addition-
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al blood product transfusions given as required, was clini-
cally successful.
John H. Lemmer, Jr, MD
Legacy Good Samaritan Hospital
NW Surgical Associates
2222 NW Lovejoy, No. 315
Portland, OR 97210
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Reply to the Editor:
Lemmer raises a number of interesting points with regard
to the removal of abciximab (ReoPro) during cardiopul-
monary bypass with the use of a hemoconcentrator.1
First, as correctly pointed out, the experiments were ini-
tially carried out with normal saline solution, as a proof of
principle. However, as stated in the article, the experiments
were repeated with the use of packed red cells to maintain
clinical relevance. As the free abciximab is biologically
active (Eli Lilly and Company data sheet), then our protocol,
even though simplified, was clinically relevant.
Second, with regard to analyzing native platelet function,
platelet dysfunction after cardiopulmonary bypass occurs for
a myriad of known and unknown preoperative and periopera-
tive reasons, making the evaluation of an intervention diffi-
cult. The aim of this study was to demonstrate a technique to
reduce the inhibition of transfused platelets that occurs as a
result of abciximab inactivation. This should result in a
reduction of postoperative platelet transfusion requirements
and transfusion-related complications, for example, adult res-
piratory distress syndrome. We make no claims to reversal of
the effect of abciximab on native platelets. However, by
implication from our results and the fact that abciximab bind-
ing is known to be a reversible process, hemofiltration will
result in at least a partial reversal of the effect of abciximab
on native platelets.
Third, Lemmer states that the dissociation of abciximab
from platelets is slow, but he then states that abciximab redis-
tribution from native platelets to transfused platelets occurs
immediately after their administration, a kinetics contradic-
tion. Either a platelet-to-platelet interaction occurs (microag-
gregation, which is known not to be the case) or free abcix-
imab is involved. It is this free abciximab that Lemmer quite
rightly implicates in causing transfused platelet dysfunction,
which we demonstrated can be reversed.
Care should be taken with regard to interpretation of per-
centage glycoprotein IIb/IIIa receptor binding as evaluated in
reference 3 provided by Lemmer, since no platelet function
tests were performed, just fluorescence-activated cell sorter
analysis, which does not necessarily correlate with physio-
logic function. The prior administration of aspirin or clopido-
grel, for example, will result in an uninterpretable result in
this situation.
In addition to abciximab (ReoPro), tirofiban (Aggrastat)
and eptifibatide (Integrilin) are also specific glycoprotein
IIb/IIIa inhibitors. The possible reversal of bleeding caused
by glycoprotein IIb/IIIa inhibition therapy via hemofiltration
is now alluded to by the drug information data sheets pro-
duced by Merck, which manufactures Aggrastat, and COR
Therapeutics, Inc, and Key Pharmaceuticals, Inc, which man-
ufacture Integrilin.
Unfortunately, we do not have access to the publication of
Lemmer’s group (in press). It would be interesting to note
what degree of preoperative platelet inhibition was present in
their patients, since it is widely known that abciximab has a
variable clinical effect. Conventional platelet function tests
are impractical in an emergency situation. However, we have
recently demonstrated a quick, simple test of platelet inhibi-
tion caused by abciximab, via the technique of whole blood
microaggregation, which involved the use of a standard labo-
ratory Coulter counter (Coulter Electronics, Inc, Hialeah,
Fla).3 This should aid in assessing preoperative platelet inhi-
bition, thus making it possible to rank patients by their sus-
ceptibility to bleeding, so that accurate evaluation of any
antibleeding strategy can be ascertained.
Michael Poullis, MD
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